These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 3329185)
1. Management of iron overload in the pediatric patient. Cohen A Hematol Oncol Clin North Am; 1987 Sep; 1(3):521-44. PubMed ID: 3329185 [TBL] [Abstract][Full Text] [Related]
2. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Giardina PJ; Grady RW Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288 [TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909 [TBL] [Abstract][Full Text] [Related]
4. Clinical spectrum of iron overload, novel uses of iron chelators, and potential treatment of pediatric anemias with erythropoietin. Introduction. Cairo MS Am J Pediatr Hematol Oncol; 1990; 12(1):1-3. PubMed ID: 2178456 [No Abstract] [Full Text] [Related]
5. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575 [TBL] [Abstract][Full Text] [Related]
6. Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias. Ault P; Jones K Clin J Oncol Nurs; 2009 Oct; 13(5):511-7. PubMed ID: 19793708 [TBL] [Abstract][Full Text] [Related]
7. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias. Kwiatkowski JL; Cohen AR Hematol Oncol Clin North Am; 2004 Dec; 18(6):1355-77, ix. PubMed ID: 15511620 [TBL] [Abstract][Full Text] [Related]
8. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307 [TBL] [Abstract][Full Text] [Related]
9. Concepts and goals in the management of transfusional iron overload. Porter JB Am J Hematol; 2007 Dec; 82(12 Suppl):1136-9. PubMed ID: 17968973 [TBL] [Abstract][Full Text] [Related]
10. [Chelating therapy in beta-thalassemia]. Musumeci S; Romeo MA; Di Gregorio F; SchilirĂ³ G; Russo G Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040 [TBL] [Abstract][Full Text] [Related]
11. Recent acquisitions in the management of iron overload. Franchini M Ann Hematol; 2005 Oct; 84(10):640-5. PubMed ID: 16025271 [TBL] [Abstract][Full Text] [Related]
13. Iron loading and its clinical implications. Hershko C Am J Hematol; 2007 Dec; 82(12 Suppl):1147-8. PubMed ID: 17963253 [TBL] [Abstract][Full Text] [Related]
14. Recognition and treatment of iron overload. Brown EB Adv Intern Med; 1980; 26():159-86. PubMed ID: 7013439 [No Abstract] [Full Text] [Related]